Home Sitemap Contact us Accessibility Statement Top of the page
  • Effentora (fentanyl buccal tablet) from Teva


    (fentanyl buccal tablet)

Prescribing Effentora®

Effentora® (fentanyl buccal tablet)

Therapeutic Indications

Effentora® is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.1

Patients receiving maintenance opioid therapy are those who are taking at least 60mg of oral morphine daily, at least 25mcg of transdermal fentanyl per hour, at least 30mg of oxycodone daily, at least 8mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.1

Facts about Effentora®

Rapid pain relief as early as 10 minutes.2

Effentora® maintains effective fentanyl plasma levels for approximately 1 hour.3

93% of patients rated the onset of action of Effentora® as good to excellent.4

Treatment with Effentora® reduced the pain intensity of breakthrough cancer pain (BTcP) episodes to a mean score of 2.3 and 1.9 after 4 and 8 weeks, respectively.2

About Effentora®

Pain for healthcare professionals

Effentora® is a buccal tablet. It is flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “1”.

Each buccal tablet contains 100mcg / 200mcg / 400mcg / 600mcg / 800mcg fentanyl (as citrate).

Excipient(s) with known effect: Each tablet contains 20mg of sodium (except Effentora® 100mg which contains 10mg of sodium).

For the full list of excipients, see Section 6.1. of the Summary of Product Characteristics.

Marketing Authorisation

Swensweg 5
2031 GA Haarlem
The Netherlands

Marketing Authorisation Number(s)

  • EU/1/08/441/001 - 010

Resources for Effentora®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect
Medicine supporting documentation for Effentora®

1 Effentora® (fentanyl buccal tablet) Summary of Product Characteristics.

2 Data on File.

3 Durfee S, Messina J, Khankari R. Fentanyl Effervescent Buccal Tablets. Enhanced Buccal Absorption. Am J Drug Deliv 2006; 4: 1-5.

4 Weinstein SM, Messina J, Xie F. Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain in Opiod-Tolerant Patients With Chronic Cancer Pain: A Long-term, Open-Label Safety Study. Cancer 2009; 115: 2571-2579.

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a